Conventional cytotoxic therapy options in R/R cHL
| Agent . | Study design . | Median age (range), years . | Total, N . | Prior AHCT (n) . | ORR% (CR%) . | Median PFS/EFS (mo) . | Reference . |
|---|---|---|---|---|---|---|---|
| Gemcitabine based | |||||||
| Gemcitabine | II | 35 (19-58) | 23 | 0 | 39 (9) | 6.7 | Santoro et al8 |
| GDP | II | 36 (19–57) | 23 | 0 | 69 (17) | NR | Baetz et al9 |
| GVD | I/II | 33 (19–83) | 91 | 40 | 70 (19) | 8.5* | Bartlett et al10 |
| IGEV | II | 30 (17-59) | 91 | NA | 81 (54) | 3-y FFP 53% | Santoro et al11 |
| Platinum based | |||||||
| ICE | II | 27 (12-59) | 65 | NA | 88 (26) | 58%† | Moskowitz et al12 |
| DHAP | II | 34 (21-64) | 102 | NA | 89 (21) | NR | Josting et al13 |
| ESHAP | II | 34 (18-66) | 22 | 2 | 73 (40) | 3-y DFS 27% | Aparicio et al14 |
| Vinca alkaloids | |||||||
| Vinblastine | II | 31 (23-48) | 17 | 17 | 59 (12) | 8.3 | Little et al15 |
| Vinorelbine | II | NR | 24 | 4 | 50 (14) | 6 | Devizzi et al16 |
| Alkylators | |||||||
| Bendamustine | II | 34 (21–75) | 35 | 27 | 53 (33) | 5.2 | Moskowitz et al17 |
| Agent . | Study design . | Median age (range), years . | Total, N . | Prior AHCT (n) . | ORR% (CR%) . | Median PFS/EFS (mo) . | Reference . |
|---|---|---|---|---|---|---|---|
| Gemcitabine based | |||||||
| Gemcitabine | II | 35 (19-58) | 23 | 0 | 39 (9) | 6.7 | Santoro et al8 |
| GDP | II | 36 (19–57) | 23 | 0 | 69 (17) | NR | Baetz et al9 |
| GVD | I/II | 33 (19–83) | 91 | 40 | 70 (19) | 8.5* | Bartlett et al10 |
| IGEV | II | 30 (17-59) | 91 | NA | 81 (54) | 3-y FFP 53% | Santoro et al11 |
| Platinum based | |||||||
| ICE | II | 27 (12-59) | 65 | NA | 88 (26) | 58%† | Moskowitz et al12 |
| DHAP | II | 34 (21-64) | 102 | NA | 89 (21) | NR | Josting et al13 |
| ESHAP | II | 34 (18-66) | 22 | 2 | 73 (40) | 3-y DFS 27% | Aparicio et al14 |
| Vinca alkaloids | |||||||
| Vinblastine | II | 31 (23-48) | 17 | 17 | 59 (12) | 8.3 | Little et al15 |
| Vinorelbine | II | NR | 24 | 4 | 50 (14) | 6 | Devizzi et al16 |
| Alkylators | |||||||
| Bendamustine | II | 34 (21–75) | 35 | 27 | 53 (33) | 5.2 | Moskowitz et al17 |
Median EFS was not reached in the transplant-naive group, while it was 8.5 months in patients with prior transplant.
At a median follow-up of 43 months, as analyzed by intent to treat, the EFS was 58%.
ASCT, autologous hematopoietic cell transplantation; DFS, disease-free survival; DHAP, dexamethasone, high-dose cytarabine, cisplatin; EFS, event-free survival; ESHAP, etoposide, methylprednisolone, high-dose cytarabine, cisplatin; FFP, freedom from progression; GDP, gemcitabine, dexamethasone, cisplatin; GVD, gemcitabine, vinorelbine, liposomal doxorubicin; ICE, ifosfamide, carboplatin, etoposide; IGEV, ifosfamide, gemcitabine, etoposide, vinorelbine; NA, not applicable; NR, not reported; PFS, progression-free survival.